Flushing was described as the reason for discontinuing therapy for 6% of patients receiving Niaspan in pivotal studies
(Link) Lawsuits for Humana, HCA: Humana is facing a lawsuit alleging the use of an algorithm to deny care to Medicare Advantage patients and dont forget UnitedHealths fiasco along similar lines with naviHealth
INR monitoring should be individualized based on clinical factors, with particular attention during significant weight loss or dietary changes
Theyre asking, What will this do to our budget? And for now, the budget impact is huge. Looking for smarter solutions The researchers say there are still ways to make GLP-1s a viable, affordable option, starting with smarter coverage decisions and targeted use
Rendering of Eli Lilly's new facility in Alabama (Credit: Eli Lilly) Eli Lilly earmarks $6B for GLP-1 pill factory in Alabama Eli Lilly will spend $6 billion to build an orforglipron factory in Huntsville, AL, the third of four new US sites the pharma giant plans Sign up to read this article for free
